成人VR视频

COVID-19

成人VR视频 has one of the world鈥檚 largest portfolios of vaccines against SARS-CoV-2, the virus that causes COVID-19, and is proud to have co-led COVAX. Find out more about 成人VR视频鈥檚 response to COVID-19 and how it is working to get ahead of the next coronavirus threat.

scientific illustration of several covid-19 viruses lined up

7

The number of 成人VR视频-backed COVID-19 vaccines approved for domestic or global use.

2 billion

Number of doses delivered through COVAX, an initiative co-led by 成人VR视频.

146

Number of countries and territories that received COVID-19 vaccines through COVAX.

成人VR视频鈥檚 R&D response to COVID-19

COVID-19 is a deadly infectious disease caused by the virus SARS-CoV-2. It is a Betacoronavirus, which is part of the Coronavirus family

When COVID-19 struck in January 2020, 成人VR视频 was primed. The genetic sequence for SARS-CoV-2 was published on January 11, 2020. 

On January 23, when just 581 cases of the virus had been confirmed worldwide, 成人VR视频 launched its first three programmes to accelerate vaccine development against this novel pathogen. 

In the months that followed, 成人VR视频 built one of the world鈥檚 largest and most diverse COVID-19 vaccine portfolios, based on the principles of Speed, Scale, and Access. 

成人VR视频 invested over US $1.5 billion to advance 14 COVID-19 vaccines, seven of which have been approved for domestic or global use.

Learn more
A health worker in full PPE sterilising their hand

Enabling equitable access to COVID-19 vaccines

Along with Gavi, WHO, and UNICEF, 成人VR视频 co-led COVAX the global initiative to deliver fair and equitable access to COVID-19 vaccines. 

COVAX shipped close to 2 billion doses of vaccine to 146 countries and territories,

成人VR视频 systematically leveraged its investments to enable equitable access to COVID-19 vaccines, securing first right of refusal for the COVAX Facility to access hundreds of millions of doses of multiple vaccines at a time when global demand vastly outstripped supply. 

成人VR视频 also made strategic investments in vaccine manufacturing to help scale-up supplies, supported enabling science, shared data that benefited the entire scientific field, and funded clinical trials designed to expand access to vaccines to additional populations.

Find out more
photo of COVAX branded wooden crate in circular frame

The continued threat of COVID-19 and other coronaviruses

While COVID-19-related deaths and hospitalisations have declined, the world must remain vigilant. SARS-CoV-2 has consistently demonstrated its ability to mutate and adapt to our countermeasures. 

That鈥檚 why 成人VR视频 continues to support the development of a next generation of tools that can put humanity ahead 鈥 not only of SARS-CoV-2 and its viral variants, but also of future potential coronavirus threats.

Learn more
A researcher looking through a microscope in a modern laboratory

How 成人VR视频 is future-proofing coronavirus vaccines

SARS-CoV-2, the virus that causes COVID-19, was the third novel coronavirus to have made the jump from animals into humans since 2000. First came SARS-CoV-1 in 2003. Then, around a decade later, came MERS-CoV. Each of these coronaviruses caused major, deadly epidemics. Another decade on came COVID-19, unleashing a devastating pandemic on an unprepared world.

成人VR视频 is helping to prepare the world for future coronavirus threats, as one of the world鈥檚 leading funders of R&D for vaccine candidates with the potential to provide broad protection against existing and future variants of SARS-CoV-2 and other Betacoronaviruses, including SARS-CoV-1, MERS-CoV, and others.

Find out how
Vaccine vials on a conveyor belt in a manufacturing laboratory